Myeloproliferative Neoplasms | Specialty

FDA Grants Priority Review to Cedazuridine/Decitabine for MDS and CMML

February 14th 2020

The FDA has granted a priority review designation to a new drug application for cedazuridine plus decitabine for the treatment of adult patients with previously untreated intermediate- and high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Dr. Bose on Treating Progression in Patients With Myelofibrosis

February 14th 2020

Prithviraj Bose, MD, discusses treatment for patients with progressive myelofibrosis.

Dr. Mesa on New Trials and Agents in the Myelofibrosis Pipeline

February 12th 2020

Ruben A. Mesa, MD, discusses new trials and agents in the pipeline in myelofibrosis.

Dr. Snyder on the Utility of Transplant in MPNs

February 11th 2020

David S. Snyder, MD, discusses the utility of transplant in myeloproliferative neoplasms.

FDA Grants Breakthrough Designation to APR-246/Azacitidine Combo in TP53-Mutant MDS

January 31st 2020

The FDA has granted a breakthrough therapy designation to the combination of APR-246 and azacitidine for the treatment of patients with myelodysplastic syndromes with a susceptible TP53 mutation.

Ruxolitinib Combo Elicits Clinical Activity in Polycythemia Vera and Myelofibrosis

January 30th 2020

The combination of ruxolitinib (Jakafi) plus low-dose pegylated interferon-a2 demonstrated an improvement in peripheral blood cell counts bone marrow cellularity and fibrosis, and symptom burden with acceptable toxicity in patients with polycythemia vera or proliferative myelofibrosis.

Navitoclax Activity Confirmed in Ruxolitinib-Resistant Myelofibrosis

January 30th 2020

Jacqueline S. Garcia, MD, discusses the design and findings of a phase II trial of navitoclax and details next steps for the BCL-XL/BCL-2 inhibitor.

Mesa Shares Insight on Fedratinib Benefit in Myelofibrosis Subgroup

January 30th 2020

Ruben Mesa, MD, discusses findings from a pooled analysis of fedratinib at full dose in patients with myelofibrosis who had low platelet counts.

Direct Oral Anticoagulants Show Prophylactic Potential in MPN-Induced Thrombosis

January 30th 2020

Srikanth Nagalla, MD, discusses the management of cancer-related thrombosis in myeloproliferative neoplasms, as well as updates in immune thrombocytopenic purpura.

Emerging Therapies in Essential Thrombocytopenia

January 30th 2020

Treating Patients With Essential Thrombocytopenia

January 30th 2020

Treatment of Myelofibrosis: Emerging Therapies

January 30th 2020

Combining Ruxolitinib With Other Agents

January 30th 2020

The Role of Fedratinib in Myelofibrosis

January 30th 2020

The Use of Ruxolitinib in Myelofibrosis

January 30th 2020

Symptom Control in Myelofibrosis

January 30th 2020

Risk Stratification in Myelofibrosis

January 30th 2020

Symptoms, Diagnosis, and QoL in Patients With Myelofibrosis

January 30th 2020

Can Hepcidin Reduce Iron Deficiency in Phlebotomy?

January 30th 2020

Role of Phlebotomy in Polycythemia Vera

January 30th 2020